Somite.ai develops large-scale foundation models for human stem cells and a full-stack platform to accelerate discovery and optimization of cell therapies. The company’s proprietary capsule-based data generation platform produces differentiation data at approximately one‑thousandth the cost of traditional methods, enabling dense, causal datasets for training powerful predictive models. Somite combines low-cost data generation, large-scale model training, and model-driven discovery to compress development timelines for cell therapies. The company announced a collaboration with AMD Ventures to pair its platform with AMD Instinct GPUs, boosting compute for model training and exploring optimization of software tools for biological data. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone, the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. Somite is based in Boston, launched operations in January 2024, and has raised approximately $60M to date. Somite AI builds DeltaStem, a foundation-model platform and associated tools to design and optimize cell differentiation protocols for scalable human cell production. Its proprietary capsule technology generates cell state transition and signaling data at roughly 1,000x the efficiency of existing methods, which feeds DeltaStem. The company plans to use the platform to advance internal therapeutic programs including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders. Somite positions DeltaStem as a generalizable foundation model for developmental biology, aiming to deliver protocols with improved purity, scalability, and reliability. The company reported closing a Series A financing of more than $47 million to accelerate platform development and key programs. Founders and scientific leadership include Dr. Micha Breakstone and Dr. Jonathan Rosenfeld alongside noted academic co‑founders such as Olivier Pourquié, Allon Klein, Jay Shendure, and Cliff Tabin. Somite Therapeutics builds AI foundation models (AlphaStem) that generate large datasets to design and produce human tissues for cell-replacement therapies. The company focuses on developing scalable cell therapies for diseases such as diabetes, obesity, and muscular dystrophies, and its pipeline includes SMT-M01 for Duchenne muscular dystrophy and SMT-B01 for metabolic disorders. Somite plans to use generated data to iteratively improve its platform and expand therapy creation across broader indications. The team is led by founder and CEO Dr. Micha Breakstone and includes senior scientific and translational leaders and prominent academic co-founders. Financially, Somite completed a $4.8M extension of its pre-seed round, bringing total funds raised to over $10M. The new capital is earmarked to expedite data generation for AlphaStem, advance SMT-M01 toward the clinic, initiate the SMT-B01 program, and begin research with hypoimmune cell lines. Somite is a Boston, MA–based developer of AI for stem cell biology building foundation models to produce human tissue for cell therapies. Its proprietary AlphaStem AI platform generates massive datasets that improve the platform and enable therapy creation through rapid optimization cycles. The company focuses on producing cells derived from somites — including muscle, brown adipose, cartilage, bone, tendon, and dermis — to address diseases such as diabetes, obesity, and muscular dystrophies. Somite is also pioneering a computational digital twin of the embryo that draws on scRNA-Seq, scATAC-seq, and gene expression databases to mirror development and identify regulators of cell differentiation. The team combines AI and developmental biology expertise and includes CEO and co-founder Micha Breakstone alongside scientific co-founders such as Olivier Pourquie, Allon Klein, and Cliff Tabin. The company raised funding to continue development of AlphaStem and advance its platform.

Total raised

$57M

Funding rounds

4

Latest round

Series A

Latest activity

May 2025